Literature DB >> 1636575

Plasma plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary spastic angina.

T Masuda1, H Yasue, H Ogawa, I Misumi, T Sakamoto, H Okubo, Y Miyao, H Kato.   

Abstract

Plasminogen activator inhibitor (PAI) activity and tissue plasminogen activator (TPA) antigen were measured in venous samples in 14 patients with unstable angina consisting of eight patients with organic stenosed coronary arteries and six patients with coronary spastic angina (unstable angina group); in 14 patients with stable exertional angina (stable exertional angina group); and in 14 patients with chest pain syndrome (chest pain syndrome group). The plasma levels of PAI activity were higher (p less than 0.01) in the unstable angina group than in the stable exertional angina group and the chest pain syndrome group (12.3 +/- 1.0 versus 5.1 +/- 0.7 and 4.8 +/- 0.6 IU/ml). The plasma levels of TPA antigen were also higher (p less than 0.05) in the unstable angina group than in the stable exertional angina group and the chest pain syndrome group (10.2 +/- 1.3 versus 6.5 +/- 0.8 and 6.0 +/- 0.7 ng/ml). There were no significant differences in PAI activity and TPA antigen levels between the stable exertional angina group and the chest pain syndrome group. Furthermore, both PAI activity and TPA antigen levels in the unstable angina group decreased to the levels in the stable exertional angina group and the chest pain syndrome group after treatment (p less than 0.01). In conclusion, the increased plasma PAI activity in patients with unstable angina and in those with coronary spastic angina indicates that the fibrinolytic system is impaired in these patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1636575     DOI: 10.1016/0002-8703(92)90592-j

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  4 in total

Review 1.  Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.

Authors:  A J Wagstaff; J C Gillis; K L Goa
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

2.  Circadian variation in fibrinolytic activity in patients with variant angina.

Authors:  T Masuda; H Ogawa; Y Miyao; Q Yu; I Misumi; T Sakamoto; H Okubo; K Okumura; H Yasue
Journal:  Br Heart J       Date:  1994-02

3.  Prothrombotic profile in patients with vasospastic or non vasospastic angina and non significant coronary stenosis.

Authors:  Jaume Figueras; Jasone Monasterio; Enric Domingo; Beatriz Meneses; Elsa Nieto; Josefa Cortadellas; David Garcia-Dorado
Journal:  Thromb J       Date:  2011-05-27

4.  Layered Plaque in Organic Lesions in Patients With Coronary Artery Spasm.

Authors:  Takeshi Nishi; Teruyoshi Kume; Ryotaro Yamada; Hiroshi Okamoto; Satsohi Koto; Masahiro Yamashita; Masahiko Ueno; Kyo Kamisaka; Yoshitaka Sasahira; Ayano Enzan; Yasuyuki Sudo; Tomoko Tamada; Terumasa Koyama; Koichiro Imai; Yoji Neishi; Shiro Uemura
Journal:  J Am Heart Assoc       Date:  2022-03-24       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.